Statements (80)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Karyopharm_Therapeutics
|
| gptkbp:advocacy |
Support groups
|
| gptkbp:awards |
Industry recognition
|
| gptkbp:business_model |
B2 B and B2 C
|
| gptkbp:ceo |
gptkb:Dr._Johnson_Lau
|
| gptkbp:clinical_trial |
Ongoing
Diverse patient populations Published studies Phase I, II, and III trials Safety and efficacy studies Multinational studies Patient recruitment ongoing |
| gptkbp:collaborations |
Academic institutions
Joint ventures Partnerships with universities |
| gptkbp:community_engagement |
Philanthropic initiatives
|
| gptkbp:conducts_research_on |
gptkb:Dr._Richard_A._H._Lee
|
| gptkbp:economic_impact |
New geographic regions
|
| gptkbp:employees |
Over 500
|
| gptkbp:financial_performance |
Publicly traded
|
| gptkbp:financial_reports |
Quarterly disclosures
|
| gptkbp:financial_support |
Access programs
|
| gptkbp:focus |
gptkb:Oncology
|
| gptkbp:founded |
gptkb:2017
|
| gptkbp:funding |
Grants received
|
| gptkbp:global_presence |
International operations
|
| gptkbp:has_advisory_board |
Expert consultants
|
| gptkbp:head_of_state |
Strategic partnerships
|
| gptkbp:headquarters |
gptkb:Buffalo,_New_York
|
| gptkbp:healthcare |
New treatment modalities
Affordable treatments |
| https://www.w3.org/2000/01/rdf-schema#label |
Athenex Pharma Solutions
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:instruction_set |
Multiple drug candidates
Future therapies planned |
| gptkbp:invention |
Patents filed
|
| gptkbp:investment |
Institutional investors
Research funding Shareholder communications |
| gptkbp:investment_focus |
Global market
|
| gptkbp:leadership |
Experienced management team
|
| gptkbp:market |
Competitor assessments
Industry analysis conducted |
| gptkbp:market_launch |
New therapies annually
|
| gptkbp:marketing_strategy |
Targeted therapies
Focus on innovation |
| gptkbp:mission |
Improve patient outcomes
|
| gptkbp:partnerships |
Global health organizations
Various biotech companies Collaborations with hospitals |
| gptkbp:patient_education |
Resources available
|
| gptkbp:product |
Innovative formulations
|
| gptkbp:product_quality |
Regulatory compliance
|
| gptkbp:products |
Cancer therapies
|
| gptkbp:regulatory_compliance |
FDA approved products
Compliance with FDA Timely filings |
| gptkbp:research |
Cutting-edge studies
|
| gptkbp:research_and_development |
gptkb:Yes
|
| gptkbp:research_areas |
Hematology
Solid tumors |
| gptkbp:research_focus |
Chemotherapy drugs
Novel drug delivery systems |
| gptkbp:services |
Contract manufacturing
|
| gptkbp:social_responsibility |
Community health initiatives
|
| gptkbp:stock_symbol |
ATNX
|
| gptkbp:strategic_goals |
Expand product portfolio
|
| gptkbp:subsidiaries |
gptkb:Athenex,_Inc.
|
| gptkbp:supply_chain |
Global suppliers
|
| gptkbp:sustainability_practices |
Environmental responsibility
|
| gptkbp:training |
Continuous education programs
|
| gptkbp:treatment |
Improved survival rates
|
| gptkbp:trends |
Oncology advancements
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:type_of_care |
Holistic approach.
|
| gptkbp:vision |
Innovative cancer treatments
|
| gptkbp:website |
www.athenex.com
|
| gptkbp:bfsParent |
gptkb:Athenex
|
| gptkbp:bfsLayer |
6
|